COVID-19 risk in patients with substance use disorders at Kuwait addiction treatment center

Sameh Mohamed Yousri Bondok; Marwa Mohsen Ramadan Hassan; Ayman Abdel Kader; Mohamed Helmi; Hossam Ahmed Ali

doi:10.53730/ijhs.v6nS6.11284

Authors

Sameh Mohamed Yousri Bondok
Drsamehbondok@yahoo.com
Psychiatry senior registrar, Addiction Treatment Centre, Kuwait
Marwa Mohsen Ramadan Hassan Lecturer of community medicine, Faculty of Medicine for Girls, Cairo, Al-Azhar University,
Ayman Abdel Kader Psychiatry registrar, Addiction Treatment Centre department, Kuwait
Mohamed Helmi Psychiatry registrar, Addiction Treatment Centre department, Kuwait
Hossam Ahmed Ali Psychiatry registrar, Addiction Treatment Centre department, Kuwait

Keywords:

substance use disorder, COVID-19, mental health

Abstract

Background: The COVID-19 pandemic is creating major issues for healthcare and broad social structures, exposing societal vulnerabilities. Patients with substance use disorder are considered at increased risk of COVID-19 and its more serious complications, however data on the impact of COVID-19 are lacking. The study aimed to describe the clinical characteristics and outcomes of COVID-19 on patients with substance use disorders seen at Kuwait addiction treatment center. Method: A cross sectional study was carried including all patients seen in outpatient department and/or admitted in the inpatient wards of Kuwait Addiction Treatment Center, diagnosed as substance use disorder with history of COVID-19 infection during the period from June 2021 to December 2021. Results : Among 660 substance use disorder patients, the mean age was 36± 10.1 years (94%) were men and (91.1%) were Kuwaiti. The main substance used were Opioid in (41.1%) of patients, stimulant in (25.5%) and synthetics in (11.2%) of patients. One or more comorbidities associated to COVID-19 risk were observed in (29 %) of patients. (9.1%) of patients got COVID-19 infection and 61.5% were vaccinated.

Downloads

Download data is not yet available.

References

Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796

First MB, Spitzer RL, Gibbon M, et al (1995). Structured Clinical Interview for DSM-IV Axis I Disorders-Pa-tient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute.

Garg S, Kim L, Whitaker M et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-conﬁrmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(15):458–64.

Grant BF, Saha TD, Ruan WJ, et al (2016). Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry; 73:39–47.

National Institute on Drug Abuse. COVID-19: Potential Implications for Individuals with Substance Use Disorders. Available at: https: //www.drug abuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications individuals-substance-use-disorders.

Quan Qiu Wang, David C. Kaelber, Rong Xu & Nora D (2021).Volkow Molecular Psychiatry, volume 26, pages 30–39.

Sheridan Rains L, Johnson S, Barnett P et al. Early impacts of the COVID-19 pandemic on mental health care and on people with mental health conditions: framework synthesis of international experiences and responses. Soc Psychiatry Epidemiol 2020;1–12.doi: 10.1007/s00127-020-01924-7.

Sheridan Rains L, Johnson S, Barnett P et al. Early impacts of the COVID-19 pandemic on mental health care and on people with mental health conditions: framework synthesis of international experiences and responses. Soc Psychiatry Psychiatry Epidemiol 2020 ;1–12. doi: 10.1007/s00127-020-01924-7.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals (Basel) 2020 ;13 (7):155.

WeiY, ShahR. Substance use disorder in the COVID-19 pandemic:a systematic review of vulnerabilities and complications. Pharmaceuticals (Basel) 2020;13(7):155.

Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Int J Infect Dis 2020 ;94:91–5.